Results 21 to 30 of about 29,860 (191)

The use of bedaquiline to treat patients with multidrug-resistant tuberculosis and end-stage renal disease: A case report

International Journal of Infectious Diseases, 2018
The use of bedaquiline to treat patients with multidrug-resistant tuberculosis (MDR-TB) and end-stage renal disease (ESRD) may raise safety concerns. Currently, no clinical information is available on the use of bedaquiline to treat MDR-TB patients with ...
Seyeon Park, Kyu Min Lee, Insu Kim, Jeongha Mok   +3 more
doaj   +1 more source

Prolonged use of bedaquiline in the treatment for MDR-TB in a child

IDCases, 2021
Bedaquiline (Bdq), a novel TB drug, is referred to the most effective drugs and used for the management of multidrug-resistant tuberculosis (MDR-TB). The drug produces a cardiotoxic effect, and its use is limited to six months.
Marina F. Gubkina, Julia Yu. Khokhlova, Natalia V. Yukhimenko, Irina Yu. Petrakova   +3 more
doaj   +1 more source

Comparative safety of bedaquiline and delamanid in patients with multidrug resistant tuberculosis: A nationwide retrospective cohort study

Journal of Microbiology, Immunology and Infection, 2023
Background/Purpose(s): Bedaquiline and delamanid were recently approved for multidrug resistant tuberculosis (MDR-TB). Bedaquiline carries a black box warning of increased risk of death compared to the placebo arm, and there is a need to establish the ...
Ju Hwan Kim, Hyesung Lee, In-Sun Oh, Han Eol Jeong, Sungho Bea, Seung Hun Jang, Hyunjin Son, Ju-Young Shin   +7 more
doaj   +1 more source

Evaluation of physicochemical stability and degradation kinetics of bedaquiline in hydrolytic solutions of different pH

Future Journal of Pharmaceutical Sciences, 2021
Background Tuberculosis is an infection that has high mortality rate in human as well as in animals if it remains unattained for long time. Scientists are always desirous to discover new molecules against Mycobacterium tuberculosis; one of them is ...
S. J. Rajput, P. J. Vanavi
doaj   +1 more source

Effects of Bedaquiline Combined with Fluoroquinolone and/or Clofazimine on QT Interval in Patients with Multidrug-Resistant Tuberculosis: a Retrospective Study

Microbiology Spectrum, 2023
With the application of bedaquiline (Bdq), the success rate of multidrug-resistant tuberculosis (MDR-TB) treatment has been significantly improved; however, the cardiac safety of the patients during treatment cannot be ignored. Hence, this study compared
Rong Li, Jin-Bao Ma, Hong Yang, Han Yang, Xin-Jun Yang, Yan-Qin Wu, Fei Ren   +6 more
doaj   +1 more source

In Vitro Bedaquiline and Clofazimine Susceptibility Testing in Mycobacterium abscessus

, 2022
Bedaquiline and clofazimine are increasingly used to treat infections with Mycobacterium abscessus. We determined distributions of MICs by broth microdilution for bedaquiline and clofazimine for 61 M. abscessus clinical isolates using different media and
Akdoğan Kittana, Fatma Nur, Schulthess, Bettina, Hömke, Rico, Sander, Peter   +3 more
core   +2 more sources

Adverse drug reactions in South African patients receiving bedaquiline-containing tuberculosis treatment: an evaluation of spontaneously reported cases

BMC Infectious Diseases, 2019
Background Bedaquiline was recently introduced into World Health Organization (WHO)-recommended regimens for treatment of drug resistant tuberculosis. There is limited data on the long-term safety of bedaquiline.
Jackie Jones, Vanessa Mudaly, Jacqueline Voget, Tracey Naledi, Gary Maartens, Karen Cohen   +5 more
doaj   +1 more source

Emergence of bedaquiline resistance in a high tuberculosis burden country

, 2022
Rationale: Bedaquiline has been classified as a group A drug for the treatment of multidrug-resistant tuberculosis (MDR-TB) by the World Health Organization; however, globally emerging resistance threatens the effectivity of novel MDR-TB treatment ...
Barilar, Ivan,, Crudu, Valeriu,, Utpatel, Christian, Andres, Sönke,, Maurer, Florian P., Crudu, Valeriu, Chesov, Dumitru, Heyckendorf, Jan,, Reimann, Maja, Lange, Christoph, Niemann, Stefan,, Lange, Christoph,, Donica, Ana, Maurer, Florian P.,, Chesov, Dumitru,, Reimann, Maja,, Donica, Ana,, Chesov, Elena, Utpatel, Christian,, Andres, Sönke, Barilar, Ivan, Niemann, Stefan, Merker, Matthias, Heyckendorf, Jan, Merker, Matthias,, Chesov, Elena,   +25 more
core   +1 more source

Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients [PDF]

, 2020
Genetic mutations linked to bedaquiline resistance were found before starting treatment and acquired during treatment in patients with drug-resistant TB and HIV in KwaZulu-Natal, South Africa.
Grant, Alison D, Brien, Kayleen, van Dorp, L, Nimmo, Camus, Nimmo, C, Millard, James, Pym, AS, Pym, Alexander S, van Dorp, Lucy, Lutchminarain, K, Balloux, F, Moodley, S, Wolf, A, O'Donnell, M, Padayatchi, Nesri, Padayatchi, N, Brien, K, Balloux, Francois, Grant, AD, Lutchminarain, Keeren, O'Donnell, Max, Moodley, Sashen, Wolf, Allison, Millard, J   +23 more
core   +1 more source

A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug-resistant tuberculosis. [PDF]

, 2019
There are limited data on combining delamanid and bedaquiline in drug-resistant tuberculosis (DR-TB) regimens. Prospective long-term outcome data, including in HIV-infected persons, are unavailable.We prospectively followed up 122 South African patients (
Esmail, Aliasgar, Limberis, Jason, Olayanju, Olatunde, Dheda, Keertan   +3 more
core   +1 more source